A Phase Ib/II Open-label, Multi-centre, Dose Finding Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Latest Information Update: 20 Mar 2023
At a glance
- Drugs Eltanexor (Primary)
- Indications Carcinoma; Nasopharyngeal cancer; Penile cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms REACH
- Sponsors Antengene Corporation
- 16 Mar 2023 Status changed from recruiting to discontinued. ( Based on the adjustment of clinical research and development strategy, sponsor decided to terminate the study)
- 29 Dec 2021 Status changed from not yet recruiting to recruiting, according to an Antengene Corporation media release.
- 29 Dec 2021 According to an Antengene Corporation media release, the first patient has been dosed in the study.